|
MARS2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.89520000000365E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.85919999999529E-05 |
| Normal-vs-Stage2 |
6.864000E-01 |
| Normal-vs-Stage3 |
7.04219999980715E-07 |
| Normal-vs-Stage4 |
4.79119999996502E-06 |
| Stage1-vs-Stage2 |
1.723530E-02 |
| Stage1-vs-Stage3 |
4.326400E-02 |
| Stage1-vs-Stage4 |
4.075800E-02 |
| Stage2-vs-Stage3 |
1.116620E-03 |
| Stage2-vs-Stage4 |
8.360900E-04 |
| Stage3-vs-Stage4 |
6.209000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.50899999995513E-06 |
| Normal-vs-AfricanAmerican |
1.455120E-03 |
| Normal-vs-Asian |
2.638700E-03 |
| Caucasian-vs-AfricanAmerican |
5.341000E-01 |
| Caucasian-vs-Asian |
8.431600E-01 |
| AfricanAmerican-vs-Asian |
5.377800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.360480E-04 |
| Normal-vs-Female |
8.12940000000095E-05 |
| Male-vs-Female |
5.410800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.236430E-04 |
| Normal-vs-Age(41-60Yrs) |
1.16260000004864E-06 |
| Normal-vs-Age(61-80Yrs) |
3.813900E-02 |
| Normal-vs-Age(81-100Yrs) |
1.484360E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.478000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.103960E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.352600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.473810E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.593600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.101000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.601500E-02 |
| Classical-VS-Follicular |
5.901700E-03 |
| Classical-VS-Other |
2.255400E-01 |
| Classical-VS-Normal |
3.75429999999177E-06 |
| Tall-VS-Follicular |
2.402700E-04 |
| Tall-VS-Other |
6.899200E-01 |
| Tall-VS-Normal |
2.5162000000245E-06 |
| Follicular-VS-Other |
8.910200E-02 |
| Follicular-VS-Normal |
2.927200E-01 |
| Other-VS-Normal |
1.010490E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.160930E-03 |
| Normal-vs-N1 |
3.36329999961471E-07 |
| N0-vs-N1 |
2.556700E-03 |
|
|
